Reuters logo
FDA tentatively approves Eagle Pharma's cancer drug
October 27, 2017 / 7:16 PM / 2 months ago

FDA tentatively approves Eagle Pharma's cancer drug

Oct 27 (Reuters) - Eagle Pharmaceuticals Inc said on Friday that the U.S. Food and Drug Administration tentatively approved its injectable drug to treat a most common type of lung cancer and a cancer of mesothelial tissue.

The drug, Pemfexy, is a diluted version of Eli Lilly and Co’s top-selling oncology treatment, Alimta, which raked in sales of $2.28 billion in 2016.

A tentative approval means the drug is not eligible for marketing in the United States because of existing patent protections. (Reporting by Divya Grover in Bengaluru; Editing by Sriraj Kalluvila)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below